Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
5-Amino-1MQ: Research & Evidence
Early-Stage ResearchPublished research, clinical trial data, and evidence grading for 5-Amino-1MQ across studied indications.
Back to 5-Amino-1MQ overviewResearch Summary
5-Amino-1MQ has zero human studies — it exists entirely in preclinical research. Mouse studies show NNMT inhibition reduces weight gain and improves metabolic markers, but no human pharmacokinetic, safety, or efficacy data exists. Classified as a small molecule quinolinium compound rather than a classical peptide.
Evidence by Indication (2 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Fat metabolism / obesity | Tier D | 0 | NNMT inhibition reduces fat mass in mouse models; zero human data |
| NNMT inhibition | Tier D | 0 | Mechanism well-characterized in vitro; no human clinical data exists |
Graded using our evidence tier methodology.
Citations (2 sources)
- 1. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Study
(2024), Diabetes, obesity & metabolism
- 2. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Study
Dimet-Wiley A, Wu Q, Wiley JT, et al. (2022), Scientific reports